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Background. Treatment of intractable pain due to chemotherapy induced peripheral neuropathy (CIPN) is a challenge. Intravenous
(iv) lidocaine has shown to be a treatment option for neuropathic pain of different etiologies.Methods. Lidocaine (1.5mg/kg in 10
minutes followed by 1.5mg/kg/h over 5 hours) was administered in nine patients with CIPN, and analgesic effect was evaluated
during infusion and after discharge. The immediate effect of lidocaine on pressure pain thresholds (PPT) and the extent of the
stocking and glove distribution of sensory abnormalities (cold and pinprick) were assessed. Results. Lidocaine had a significant
direct analgesic effect in 8 out of 9 patients (𝑃 = 0.01) with a pain intensity difference of >30%. Pain reduction persisted in 5
patients for an average of 23 days. Lidocaine did not influence mean PPT, but there was a tendency that the extent of sensory
abnormalities decreased after lidocaine. Conclusion. Iv lidocaine has direct analgesic effect in CIPN with a moderate long-term
effect and seems to influence the area of cold and pinprick perception. Additional research is needed, using a control group and
larger sample sizes to confirm these results.
1. Introduction
Chemotherapy induced peripheral neuropathy (CIPN) is a
clinically relevant side effect of various chemotherapeutic
drugs that prevents an optimal treatment regimen in a signif-
icant proportion of patients [1, 2]. Although CIPN has been
described with many chemotherapeutic drugs, the occur-
rence and severity of CIPN depend on the type of chemother-
apeutic drug, regimen, cumulative dose, and individual
patient factors [3]. CIPN has a relatively high prevalence,
varying from 68.1% within the first month after cessation of
chemotherapy to 30%at sixmonths or later [4]. Severalmech-
anisms have been described to explain the underlying patho-
physiology of CIPN. Alterations in ion channel function,
mainly sodium channels, are believed to play an important
role in the pathophysiology of CIPN.These alterations induce
changes in the cell membrane leading to spontaneous electric
discharges, resulting in a hyperexcitability state of the nervous
system [5, 6]. Additionally, increased release of inflammatory
cytokines is believed to contribute to occurrence of chronic
neuropathic pain and CIPN [3, 7].
Clinically, CIPNmainlymanifests as a sensory peripheral
neuropathy, althoughmotor and autonomic nerve fibers may
also be involved [2, 4]. The sensory neuropathy is often
distributed in a “stocking and glove” manner (i.e., affecting
the feet, distal lower legs, and hands) and causes symptoms
like pain, sensory loss, allodynia, paresthesia, numbness, and
tingling [2, 3, 8]. Symptoms frequently affect patients’ daily
activities and decrease their quality of life [2, 3]. Until now,
no sufficient treatment option has been available for CIPN.
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Intravenous (iv) lidocaine has shown to be a successful option
in treating various causes of chronic neuropathic pain [5, 9–
11]. The first description of iv lidocaines’ analgesic effect was
in 1961, but with a high incidence of side effects at doses
required for pain relief [12]. A report of Boas et al. in 1982
led to the analgesic use of lidocaine incline [13]. Lidocaine,
a nonspecific sodium channel blocker, reduces ectopic nerve
discharges, relieves hyperalgesia, and modulates the inflam-
matory response, because of an inhibitory effect on sodium,
calcium, and potassium ion channels, G-protein coupled
pathways, NMDA receptors, and the glycinergic system [14].
No study has been conducted yet to determine the effect of
iv lidocaine on neuropathic pain in patients with CIPN, but
theoretically itmight be a potentially useful treatmentmodal-
ity. We experienced that iv lidocaine had an analgesic effect
in individual patients with CIPN, and in some of them the
stocking and glove distribution of sensory deficits changed.
Therefore, our primary aim was to investigate the effect of a
single infusion of iv lidocaine on neuropathic pain in patients
withCIPN, and additionallywe examined sensory symptoms.
2. Material and Methods
2.1. Patients. Patients were recruited in the period of January
2015 until November 2015 from the outpatient pain clinic
of the Radboud University Medical Center, Nijmegen, The
Netherlands. Patients aged 18 years or older, diagnosed
with CIPN, who had a pain score of 5 or more on an 11-
point numeric rating scale (NRS), were included. Exclusion
criteria were last chemotherapy infusion < 12 weeks ago,
myocardial ischemia < 6 months ago, cardiac arrhythmias or
use of antiarrhythmic medication, nephropathy (glomerular
filtration rate < 60ml/min/1.73m2), liver disease (serum
bilirubin > 1.5 × above normal), hypokalemia, a known
allergy for local anesthetics of the amide-type, diabetes
mellitus or other known peripheral neuropathic disease, and
pregnancy or lactation. Concomitant use of other analgesics
drugs at the moment of inclusion was continued if necessary,
without dosage modifications. Demographic characteristics
like age, gender, medical history, previous analgesics usage,
and Hospital Anxiety and Depression Scale (HADS) were
collected. Patients completed the National Cancer Institute-
Common Toxicity Criteria (NCI-CTC) questionnaire before
treatment with lidocaine. The NCI-CTC questionnaire is
used to determine the grade of neuropathy, ranging from
0 to 4, where 0 corresponds to no neuropathic symptoms
and 4 to the most severe neuropathic symptoms [15]. The
HADS is a questionnaire to determine the level of anxiety
and depression, with a maximum of 42 points [16, 17]. A total
HADS > 12 (sensitivity 0.80 and specificity 0.74) indicates
a state of depression or emotional distress [18]. The study
protocol was approved by the institutional review board and
participants gave informed consent to use their data.
2.2. Treatment. The study used a prospective observational
cohort design. Patients received the following regimen of
iv lidocaine: a bolus of 1.5mg/kg, infused in 10 minutes,
followed by continuous infusion of lidocaine 1.5mg/kg/h over
a 5-hour period. This infusion algorithm is selected since
the analgesic effect seems to be correlated with duration of
infusion [11], and therapeutic plasma levels for pain treatment
are within 1–5 𝜇g/ml [19, 20]. Plasma levels of 2–4 𝜇g/ml will
be achieved with a bolus of 2mg/kg followed by continuous
infusion 2-3mg/kg [21], though awake patients can experi-
ence unwanted side effects when using these dosage schemes.
A three-lead electrocardiogram, blood pressure, and
oxygen saturation were monitored continuously throughout
the study by an anaesthesiologist. Patients were observed
for possible side effects till approximately 30–60 minutes
after treatment with lidocaine; during this period no study
measurements were performed. All measurements were per-
formed by two clinicians (physician and medical student).
2.3. Clinical Pain Score. The intensity of pain was assessed
using the numeric rating scale (NRS, 0: no pain, 10: worst
pain imaginable) [22]. Pain ratings were obtained directly
before start of infusion, every 15 minutes during the first
hour, and subsequently every 30 minutes until the end
of infusion. During lidocaine infusion, pain ratings were
obtained separately for both hands and both feet. Correlation
between duration of infusion and pain ratings was assessed.
The difference between the NRS at baseline and the NRS
after treatment with iv lidocaine was used to calculate the
absolute pain intensity difference (PID) and the percentage
pain intensity difference (PID%). An absolute decrease in
pain intensity scores of ≥2 points on the NRS or a PID% of
≥30% was considered clinically significant [23]. Patients with
a clinical significant result were defined as responders. The
other patients were seen as nonresponders.
The duration of the analgesic effect after discontinuation
of lidocaine infusion was assessed by number of consecutive
days till painwas returned to baseline. Patients received a pain
diary, in which pain scores were asked 3 times daily, from
days 0–10 every day, from day 14, and further weekly. They
were called by the physician every 3 weeks after infusion, who
asked if there has been any prolonged analgesic effect and
what the duration of this effect was. If pain was returned to
baseline, alternative pain management was discussed; and if
there was still pain reduction, they were called again after 3
weeks.
2.4. Examination Sensory Symptoms. Pain sensitivity and
sensory changes of the hand and feet were examined directly
before and after treatment with lidocaine. The order of
examination was successively as follows: (1) pressure pain
thresholds, (2) mechanical sensory testing, and (3) thermal
sensory testing.
2.4.1. Pressure Pain Thresholds. Baseline pain sensitivity was
assessed by measuring the responses evoked by mechanical
non invasive stimuli, that is, pressure pain thresholds (PPT)
[24]. PPT assessment has proven to be a method with
satisfactory intraindividual reproducibility and reliability [25,
26] and can easily be determined by a trained professional
with a pressure algometer [27].
A hand-held pressure algometer (Wagner force ten
FDX digital force gage) with a contact area of 1 cm2 was
used to give a standardized pressure stimulus of 50 kPa/s.
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(1)
(2)
Δ
Figure 1: Method of thermal and mechanical testing. (1) Distance
between point of sensory change and digitus III before iv lidocaine.
(2) Distance between point of sensory change and digitus III after iv
lidocaine. Δ: change in distance before and after treatment with iv
lidocaine.
PPT was assessed on both the right and left body side at
the following locations: m. trapezius pars medialis, thenar
eminence, m. rectus femoris (15 cm above patella), and the
m. abductor hallucis. Patients received instructions to notify
the investigator if their PPT was reached; subsequently the
associated pain score (NRS) was obtained. To familiarize
patients with the method of testing, measurements started
with a pressure stimulus on the ventral side of the chest.
2.4.2. Mechanical andThermal Sensory Testing. The distribu-
tion of the sensory neuropathy was measured with a Tip-
Therm stored on ice and a MRC PinPrick stimulator of
256mN. In order to assess the location of sensory changes,
cold and pinprick stimuli were repeatedly delivered on the
arm and leg. Stimuli were given from the anterior attachment
of them. deltoideus to digitus III, respectively, from the top of
the patella to the hallux. Patients had to indicate the location
of sensory change. The distance (cm) between this position
and, respectively, digitus III or the hallux represented the
extent of the distribution (Δ).Themethod of testing is shown
in Figure 1. To familiarize patients with themethod of testing,
measurements started with a pinprick and cold stimulus on
the ventral side of the chest.
2.5. Statistical Analysis. Continuous data were expressed as
means ± standard deviation or as means with a two-tailed
95% confidence interval in case of normally distributed data.
The Kolmogorov-Smirnov test was used to assess if data were
normally distributed. Skewed data are presented as median
with interquartile range (IQR). Paired data were analyzed
using the paired 𝑡-test or the Wilcoxon signed rank test,
depending on the distribution. A Pearson correlation coeffi-
cient was calculated to detect a correlation between duration
of infusion and NRS. The Bonferroni correction was used
for multiple comparisons adjustment. Statistical Package for
Social Sciences, Version 22.0 (IBM Corporation, Armonk,
NY, USA), was used for statistical analysis. Figures were
created using GraphPad Prism, Version 5.03 (GraphPad
Software Inc., La Jolla, CA, USA). A 𝑃 value less than 0.05
was considered to be statistically significant. The Bonferroni
corrected 𝑃 value considered for statistical significance is
equal to 0.006.
3. Results
3.1. Patient Characteristics. Nine patients, 4 males and 5
females (mean age 52.7 ± 11.9), were included during the
study period. Patient characteristics are depicted in Table 1.
Patients were treated for various types of malignancies with
one ormore chemotherapeutic agents, which all could induce
CIPN. Seven patients suffered neuropathy grade 4; 1 patient
reported neuropathy grade 2; and another reported neuropa-
thy grade 1 on the NCI-CTC scale. The median of the HADS
value was 17 (IQR: 8.25–18.25). All patients reported pain
in the lower extremities; 6 patients also experienced pain in
the upper extremities. Most patients had already tried a wide
variety of analgesics (e.g., NSAIDS, opioids, antidepressants,
and antiepileptics), but none were previously treated with iv
lidocaine. During treatment with lidocaine no serious side
effects occurred. All patients remained respiratory and hemo-
dynamically stable (no cardiac arrhythmias were observed)
and could be discharged within one hour after infusion.
3.2. Effect on Clinical Pain Score. Treatment with iv lidocaine
caused a clinically significant decrease in the NRS score at
group level (𝑃 = 0.01). Eight out of 9 patients experienced
an analgesic effect of lidocaine. The mean NRS score was 7.7
(NRS 5–9) before infusion and dropped to a mean NRS score
of 3.1 (NRS 0–7) after treatment.
The effect of iv lidocaine on pain (NRS scores) for every
patient is presented in Table 2 and the change in mean NRS
scores during infusion is displayed in Figure 2. NRS scores
of both hands and feet correlated significantly with duration
of infusion; the correlation coefficient of hands and feet was
−0.8 (𝑃 < 0.01) and −0.9 (𝑃 < 0.01), respectively. At the start
of infusion patients reported a higher NRS score for their feet
(5.9±2.2) comparedwith their hands (2.4±2.3). Subsequently,
the NRS of the feet showed a larger decrease than the NRS of
the hands.
In three patients experiencing pain reduction during
lidocaine treatment, the analgesic effect disappeared almost
immediately after discontinuation of the infusion. Five
patients experienced a more sustained analgesic effect, which
varied from 3 days up to 56 days with a mean duration of 23
days.
3.3. Pressure Pain Thresholds. Comparable results were
obtained when PPTs and associated NRS scores were
expressed separately for the left and right body side; therefore
the means of left and right side measurements were used
for analysis. The effect of iv lidocaine on the pressure pain
thresholds (PPT) and associated NRS scores is shown in
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Table 2: Individual NRS scores before and directly after treatment
and duration of analgesic effect of iv lidocaine.
Patient
number
NRS
before
NRS
after PID PID%
Duration
(days)
1 9 5 4 44 7
2 8 3 5 63 0
3 9 2 7 78 28
4 8 0 8 100 0
5 5 0 5 100 3
6 8 4 4 50 0
7 8 4 4 50 21
8 7 3 4 43 56
9 7 7 0 0 0
PID: pain intensity difference.
PID%: percentage pain intensity difference.
0.0 0.5 1.0 1.5 2.0 2.5 3.0 3.5 4.0 4.5 5.0
0
2
4
6
8
Hands
Feet
(Hours)
N
RS
 (0
–1
0)
Figure 2: Comparison of NRS scores of hands and feet during
lidocaine infusion. Data are expressed as means.
Table 3. There was no significant effect of iv lidocaine on
the mean PPT and associated NRS score. The effect on PPT
before and after iv lidocaine varied between −2.31 and 1.16
N/cm2 (𝑃 = 1); and for associated NRS score the effect varied
between −0.67 and 0.06 NRS points (𝑃 = 0.204–1).
3.4.Thermal andMechanical Sensory Testing. Although indi-
vidual patients could have an asymmetrical distribution of
their stocking and glove distribution, no statistically signif-
icant difference was found between left and right side for the
distribution of sensory changes for pinprick and cold in the
whole group. Combining both limbs before and after lido-
caine infusion, the cold detection level was significantly more
caudal as the pinprick detection level (𝑃 = 0.008; difference =
6.1 cm; 95% CI [1.7–10.6]) was found. For limbs and infusion
separately, the pinprick detection level was always more cra-
nial as the cold detection level; however, in these subgroups
with less observations the difference is not always statistically
significant (𝑃 varies between 0.018 and 0.625). In 1 patient no
changes in cold or pinprick sensation were observed.
3.4.1. Influence of Lidocaine on Thermal and Mechanical Sen-
sory Testing. The changes in distribution of pinprick and cold
sensation in individual patients are presented in Table 4.
In 4 patients the area of abnormality in cold perception
decreased after infusion. Three patients reported an increase
in area in the upper or lower extremity after infusion. One
patient showed a combination of positive change in one leg
and a negative change in the other leg. The area of cold per-
ception decreased when combining the limbs in all patients
(𝑃 = 0.292; difference = 3.7 cm; 95% CI [−3.5–10.8]).
In 4 patients the area of abnormal pinprick sensation in
the upper or lower extremities decreased after infusion; in
1 patient it increased in both upper and lower extremities.
Three patients showed a combination of both increase in one
area and decrease in another. The area of abnormal pinprick
sensation decreased when combining the limbs in all patients
(𝑃 = 0.099; difference = 6.4 cm; 95% CI [−1.3–14.1]).
4. Discussion
A single infusion of lidocaine decreased pain in 8 out of 9
patients with CIPN, which was correlated with duration of iv
lidocaine infusion.The long-term analgesic effect of lidocaine
wasmoderate with amean duration of 23 days. Lidocaine had
no effect on pain sensitivity measured by PPT. The distribu-
tion of sensory abnormalities was influenced by lidocaine.
There have been other studies that assessed the effect of
iv lidocaine on neuropathic pain, but to our knowledge no
study has specifically investigated the effect of lidocaine in
CIPN. ACochrane review that included 30 RCTs showed that
iv lidocaine and its oral analogues, mexiletine and tocainide,
reduce neuropathic pain [9]. This review included heteroge-
neous studies that looked at various etiologies of peripheral
neuropathic pain (e.g., diabetic, posttraumatic, and central
pain) and lidocaine dosages also varied (1–5mg/kg in 30–60
minutes) between studies. Tremont-Lukats et al. investigated
three dosing regimens of lidocaine (1, 3, and 5mg/kg/hr
during 6 hours) in various neuropathic pain syndromes. Pain
scores continued to decrease till 4 hours after start of lido-
caine infusion. Lidocaine at 5mg/kg/hr was more effective at
relieving neuropathic pain than lower dosages, and this effect
persisted for at least 4 hours after end of infusion [11]. Three
other studies investigated the effect of lidocaine in homoge-
nous patient groups. In two small groups of patients with
peripheral nerve injury, lidocaine (5mg/kg in 30 minutes
or 4 hours) had conflicting analgesic efficacy and long-term
effects were not evaluated [28, 29]. Lidocaine (5mg/kg or
7.5mg/kg in 4 hours) had a significant effect in reducing pain
in a group of 15 patients with intractable diabetic neuropathy.
This effect lasted for up to 28 days [30], which is comparable
to our results.
4.1. Sensory Testing. PPT is increasingly used to compare pain
sensitivity before and after treatment [31, 32]. No influence of
lidocaine was found on PPT and associated NRS. Previous
studies investigating the analgesic effect of agents targeting
neuronal excitability have shown that pretreatment pressure
pain thresholds can predict analgesic efficacy of treatment
[33]. In our study, no correlation between pressure pain
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Table 4: The change in distance (Δ) for cold and pinprick stimuli before and after treatment with iv lidocaine.
Patient number
Cold Pinprick
Arm Leg Arm Leg
Right Left Right Left Right Left Right Left
Δ (cm) Δ (cm) Δ (cm) Δ (cm) Δ (cm) Δ (cm) Δ (cm) Δ (cm)
1 −22 −14 −45 −3 −28 −22 −30 −41
2 0 −26 −8 −2 0 +7 +23 +17
3 −13 −11 −7 −3 −25 −16 −10 −6
4 0 0 0 0 0 0 0 0
5 0 0 +24 +45 +2 −2 −2 −3
6 0 0 0 +12 −7 −11 +27 +5
7 0 0 −8 −8 0 0 −26 0
8 0 +19 +1 0 +19 +3 −6 −6
9 0 0 −2 +6 0 0 −5 −2
thresholds and efficacy of treatment was found. The mean
pressure pain thresholds in our population were comparable
to thresholds described in healthy individuals [34].
Spread of sensory abnormalities showed a marked vari-
ance between patients; however the mean affected area for
cold detection had a tendency to be smaller than for pinprick.
Cooling the skin to 4∘C activates A-𝛿 and C-fibers sensitive
to innocuous cooling and cold-sensitive nociceptors. The
perception of pinprick pain intensity is related to activity
in A-𝛿 fiber nociceptors [35]. Krøiga˚rd et al. observed in
patients with CIPN caused by oxaliplatin and docetaxel that
mechanical detection thresholdmeasuredwith von Frey hairs
was more affected as the cold detection threshold [36]. These
results indicate that CIPN affects both small and large nerve
fibers. It has to be noted that some patients found it challeng-
ing to indicate the exact location of sensory change, possibly
resulting in a test with a lower accuracy and sensitivity.
The effect of lidocaine on the distribution of sensory
abnormalities showed unexpected results, with an increase
of sensory abnormalities in some and a decrease in other
patients. Although these changes were not statistically sig-
nificant, it is interesting that a pharmacological agent can
influence and maybe decrease sensory abnormalities. These
results could provide a basis for further research on develop-
ing treatments, including specific sodium channel blockers,
which reduce or even treat sensory disturbances in polyneu-
ropathy.
CIPN is known to be a common dose limiting side effect
of chemotherapeutic agents like taxanes, vinca alkaloids,
and platinum compounds [1, 2]. Proposed mechanisms for
taxane-induced neuropathy are a disrupted axonal micro-
tubule structure and a toxic effect on mitochondria in pri-
mary afferent neurons. Vinca alkaloids induce alterations in
neuronal cytoskeleton leading to impaired axonal transport
and degeneration. Platinum compounds accumulate in the
dorsal root ganglia resulting in decreased cellularmetabolism
and axoplasmic transport [1–3]. Most of these agents will
be combined with other types of chemotherapy in cancer
treatment, like antimetabolites, topoisomerase inhibitors, or
antitumor antibiotics, which can have equally a neuropathy
as a side effect.
In this study, patients with various types of malignan-
cies were included, who were also treated with different
chemotherapeutic agents, whichmay have resulted in hetero-
geneity of their sensory profiles. From these data no conclu-
sions can be drawn which sensory abnormalities can be seen
in CIPN caused by a specific type of chemotherapy or which
responds best to lidocaine treatment. Since several trials indi-
cate that sensory phenotyping can predict drug responsive-
ness [37, 38], a larger andmore detailed study could untangle
the different pathophenotypes of CIPN and their responsive-
ness to treatment.Drawbacks of our study are its small sample
size and lack of control group. However, despite the small
sample size, a significant direct analgesic effect was observed,
even though patients received various types of chemotherapy
and had different comorbidities. Additionally, most patients
had severe neuropathy and had previously received various
analgesics and the median HADS value was 17 [39]. These
factors can render a subjectmore susceptible to nonsuccessful
pain treatment.
5. Conclusion
Iv lidocaine, an old-school drug, significantly reduced
intractable pain in patients with CIPN for an average of 23
days in our study and there was a tendency for a decreased
extent of sensory abnormalities. Our results are therefore
promising and show a potential role for iv lidocaine in
patients with CIPN, when standard treatment algorithm
for neuropathic pain fails [40]. This might prevent them
from finishing the intended optimal chemotherapy regimen.
Furthermore, patients who do not respondwith a long lasting
effect to lidocaine can be prescribed an oral sodium channel
blocker likemexiletine, carbamazepine, or lamotrigine.These
promising results provide a basis for the development of
larger randomized trials, investigating the role of lidocaine in
the treatment of CIPN.
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